CD24 Protein-Detecting Novel Blood Test For early Colorectal Cancer Recognition

According to outcomes of a recent study performed, a new-fangled promising blood test could detect and also prevent colon cancer.

The test could identify CD24 protein which is present in high amounts in colon cancer as well as in growths that ordained to develop into colon cancer. In comparison, the CD24 protein levels are low in normal tissue.

The researchers stated that CD24 production is early on when colorectal cancer develops and could be involved in metastasis.

Colon cancer is mostly detected in later stages when the chances of recovery are usually dim. The new blood test aims at detecting the cancer early on when it is treatable.

The test could additionally be beneficial for recognizing patients for whom colonoscopy would be beneficial.

Colorectal cancer is one of the prevalent cancer types with an annual diagnosis of above 1,50,000 individuals in the United States alone. Though colonoscopies are capable of detecting the condition in its initial staging when most treatable – and also avoid it by detecting polyps prior to them turning malignant –several individuals eschew the method due to associated levels of discomforting sensations, pain and minuscule risk of complications.

There are other forms of non-invasive tests for colorectal cancer like the fecal occult blood test that detects blood presence in stool samples. However, blood presence in stools could also be indicative of a wide array of health issues, for instance, haemorrhoids which could lead to elevated rates of false-positive outcomes.

CD24 could not just forecast the existence of cancer amid less false-positive and negative rates, however could additionally identify elevated-risk pre-malignant growths. Thus their removal could help in preventing colon cancer from advancing.

Trial for Colon Cancer

During the novel study, the researchers firstly calculated CD24 protein levels in sixty-three colon cancer patients, nineteen individuals having adenoma, or pre-malignant colon growths and sixty-eight individuals is normal health.

CD24 was observed to be drastically high among people having colon cancer and adenoma in comparison to those in normal health.

They then additionally evaluated the precision of CD24 blood tests among seventy-three individuals: eleven of whom were having colon cancer, twenty-four individuals having adenomas and thirty-eight people exhibited no colon cancer symptoms.

The scientists detected that the test precisely diagnosed colorectal cancer among ninety-two percent of the cases; solely eight percent of colon cancer cases failed detection. The test showed false-positive outcomes in eight percent of the individuals that did not have cancer.

The test was able to precisely spot growths in eighty-four percent of the adenoma cases and had false-positive rate of eleven percent.

The researchers state the subsequent stride would be validating the outcomes in larger-scaled studies. The blood test would have a likely costing of fifty dollars and in case is able to pan out would prove to be an immensely beneficial device for widespread colon cancer cases.